Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$1.13 USD
+0.08 (7.62%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.13 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
Seres Therapeutics (MCRB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.08 | $10.00 | $1.00 | 288.57% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Seres Therapeutics comes to $4.08. The forecasts range from a low of $1.00 to a high of $10.00. The average price target represents an increase of 288.57% from the last closing price of $1.05.
Analyst Price Targets (3 )
Broker Rating
Seres Therapeutics currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, three are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/13/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
9/12/2024 | Not Identified | Not Identified | Hold | Hold |
6/4/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 6 |
Average Target Price | $4.08 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.24 |
MCRB FAQs
Seres Therapeutics, Inc. (MCRB) currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for Seres Therapeutics, Inc. (MCRB) is $4.08. The current on short-term price targets is based on 4 reports.
The forecasts for Seres Therapeutics, Inc. (MCRB) range from a low of $1 to a high of $10. The average price target represents a increase of $261.06 from the last closing price of $1.13.
The current UPSIDE for Seres Therapeutics, Inc. (MCRB) is 261.06%
Based on short-term price targets offered by three analysts, the average price target for Seres Therapeutics comes to $4.08. The forecasts range from a low of $1.00 to a high of $10.00. The average price target represents an increase of 288.57% from the last closing price of $1.05.